CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I/II Trial of Repeat Dosing of Super-Selective Intraarterial Infusion of Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05956821
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:52.352374+00:00
Published At: 2025-12-08T00:00:00+00:00
Record Updated At: 2025-12-08
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Glioblastoma Multiforme", "Anaplastic Astrocytoma", "Fibrillary Astrocytomas", "Oligodendroglioma", "Diffuse Intrinsic Brainstem Glioma", "Diffuse Intrinsic Pontine Glioma", "DIPG Brain Tumor", "H3 K27M"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-08"
protocolSection.identificationModule.nctId: "NCT05956821"
protocolSection.identificationModule.officialTitle: "Phase I/II Trial of Repeat Dosing of Super-Selective Intraarterial Infusion of Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.